Answers are grounded in this paper and cite their sources.
Human mesenchymal stem cells (hMSCs) are promising for cell transplantation therapies. Nevertheless, their limited yield necessitates large-scale ex vivo expansion. Microcarrier-based culture offers a scalable platform, but efficient functionalization strategies are not available. Here, we engineered collagen-binding chimeric proteins by fusing insulin-like growth factor-1 (IGF-1) and basic fibroblast growth factor (bFGF) with an osteopontin-derived collagen-binding peptide and immobilized them on type I collagen-coated poly-(vinyl alcohol) microcarriers. This single-molecule design provides the unique advantage where the surface is functionalized with a fixed molar ratio of IGF-1 to bFGF, avoiding the stoichiometric uncertainty inherent to the coimmobilization of separate proteins. Structural characterization confirmed proper folding of the chimeras, and functional assays demonstrated that dual-domain constructs markedly enhanced hMSC proliferation compared with single-factor controls, with the IGF-1-bFGF chimera yielding the highest effect. Expanded cells retained osteogenic differentiation potential. These findings demonstrate that chimeric growth factors with defined stoichiometry offer a practical and robust strategy for scalable hMSC expansion, with significant implications for regenerative medicine and cell therapy.
No takes yet. Share an insight, caveat, or question.
Pasanen et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: